When you see that a medicine is “in phase 3,” it means it is being studied in people before an FDA marketing decision—not that FDA approval has already happened. The four phases ask different questions: early safety, whether a treatment appears to help, confirmation in a larger study, and what happens after marketing. A small worked example: if 100 people are assigned to a new treatment and 100 to a comparison group, phase 3 may compare outcomes between those two groups; phase 4 may then track reports and new studies after the product is available more widely.
What happens in phases 1, 2, and 3?
Clinical development usually moves through these stages before an FDA decision. A comparison group is the group used to judge results against the treatment group. It may receive usual care or a placebo, an inactive look-alike treatment.
| Phase | Main question | Who is studied | Common comparison |
|---|---|---|---|
| Phase 1 | Can people take it safely, and how does the body handle it? | A small group, often healthy volunteers | May focus on dose and safety rather than a comparison group |
| Phase 2 | Does it appear to help for the condition being studied, and what dose should move forward? | More people with the condition | Often usual care or placebo |
| Phase 3 | Do the benefits and harms hold up in a larger group? | A much larger group of people with the condition | Often usual care or placebo |
Phase 1 is the earliest human step. Phase 2 starts testing the question a reader usually cares about: whether the treatment appears to help people with the targeted condition. Phase 3 is the larger confirmation step. The phases are useful labels, but the details matter: who joined, what outcome was measured, and what the treatment was compared with. Our guide to study populations explains why those details can change what a headline means.
What is phase 4?
Phase 4 comes after a product reaches the market. It is also called post-market surveillance, meaning continued collection of information about benefits and harms during broader use. A phase 4 study may look at longer-term outcomes or groups not well represented in earlier trials.
The main difference is timing and purpose: phase 3 is part of the premarket package used in an FDA application; phase 4 follows marketing and adds information from later use and studies. FDA also publishes guidance for industry on clinical development and related regulatory work.
How long does phase 3 take before FDA approval?
There is no single phase-3-to-approval timeline in the research cited here. A 2017 PLOS One analysis followed 138 new drugs and biologics approved by FDA from 2010 through 2014. It found a median of 8 years from the first clinical trial to first FDA approval, with a range of 4 to 20 years. That is the full clinical-development period beginning with the first human trial, not phase 3 alone.
The same study compared products that entered clinical trials before versus after the researchers’ measure of target-technology maturity. Average clinical development was 11.5 years in the earlier-entry group and 8.5 years in the later-entry group. This was a retrospective analysis of approved products, not a prediction tool for any one medicine. You can read the study’s development timeline analysis for its methods and limits.
How many phases are needed before FDA approval?
For the usual pathway described here, phases 1 through 3 come before an application for FDA review. Phase 4 is after marketing. The sequence is not a promise that a product will reach the next stage or receive approval; each stage supplies information for the next decision.
How long do phase 1 and phase 2 trials last?
There is no reliable standard length in the material reviewed here. The time depends on the treatment, condition, study design, enrollment, follow-up, and the outcomes being measured. If you are reading about a particular trial, its record should state the planned dates and follow-up. See how to read a ClinicalTrials.gov record before treating a projected date as a result.
Which phase do most trials fail?
There is no phase-by-phase failure count in the material reviewed here. A trial can stop for safety findings, results that do not improve on the comparison, practical problems, or sponsor decisions. The PLOS One analysis notes that clinical leads can fail for many reasons, including safety, how a drug moves through the body, and commercial factors. For a specific treatment, focus on the completed studies and their results rather than a general failure statistic.
Do people get paid for phase 1 trials?
Payment terms are set by the individual study. The material reviewed here does not give a standard amount or rule. A trial record and the study team can explain compensation, travel costs, time commitments, possible risks, and what happens if you leave the study.
Questions to take to a clinician or study team
- What phase is this study in, and what question is it designed to answer?
- Who was included, and how similar are they to me or the person I care for?
- What is the comparison group receiving?
- What outcome is being measured, and how long are participants followed?
- What results are available now, rather than planned for later?
- If I am considering participation, what are the costs, payments, and time commitments?
By Health Evidence Literacy Guide Editorial Team
Leave a Reply